|
Originally published In Press as doi:10.1074/jbc.M203885200 on August 20, 2002
J. Biol. Chem., Vol. 277, Issue 43, 40594-40601, October 25, 2002
JAK-STAT Signaling Mediates Gangliosides-induced Inflammatory
Responses in Brain Microglial Cells*
Ohn Soon
Kim ,
Eun Jung
Park ,
Eun-hye
Joe, and
Ilo
Jou§
From the Department of Pharmacology, School of Medicine, Ajou
University, Suwon 442-721, Korea
Received for publication, April 22, 2002, and in revised form, July 19, 2002
 |
ABSTRACT |
Neuronal cell membranes are particularly rich in
gangliosides, which play important roles in brain physiology and
pathology. Previously, we reported that gangliosides could act as
microglial activators and are thus likely to participate in many
neuronal diseases. In the present study we provide evidence that
JAK-STAT inflammatory signaling mediates gangliosides-stimulated
microglial activation. Both in rat primary microglia and murine BV2
microglial cells, gangliosides stimulated nuclear factor binding to
GAS/ISRE elements, which are known to be STAT-binding sites. Consistent with this, gangliosides rapidly activated JAK1 and JAK2 and induced phosphorylation of STAT1 and STAT3. In addition, gangliosides increased
transcription of the inflammation-associated genes inducible nitric-oxide syn- thase, ICAM-1, and MCP-1, which are
reported to contain STAT-binding elements in their promoter regions.
AG490, a JAK inhibitor, reduced induction of these genes, nuclear
factor binding activity, and activation of STAT1 and -3 in
gangliosides-treated microglia. AG490 also inhibited
gangliosides-induced release of nitric oxide, an inflammation hallmark.
Furthermore, AG490 markedly reduced activation of ERK1/2 MAPK,
indicating that ERKs act downstream of JAK-STAT signaling during
microglial activation. However, AG490 did not affect activation of p38
MAPK. We also report that the sialic acid residues present on
gangliosides may be one of the essential components in activation of
JAK-STAT signaling. The present study indicates that JAK-STAT signaling
is an early event in gangliosides-induced brain inflammatory responses.
 |
INTRODUCTION |
Gangliosides are sialic acid-containing glycosphingolipids that
are constituents of mammalian cell membranes. Gangliosides are
particularly abundant in neuronal cell membranes and participate in
various cellular events of the nervous system (1, 2). The major types
of gangliosides in the brain are GM1, GD1a, GD1b, GT1b, and GQ1b, which
differ in their profiles of sialic acid residues and carbohydrate
moieties. Several lines of evidence point to the importance of the
brain-derived gangliosides in immune responses and the pathogenesis of
brain disease. There are reports that brain injury can cause release of
gangliosides from damaged neuronal cells into the extracellular space,
which may lead to pathophysiological conditions (3-5). Gangliosides
have also been reported to interact with A , suggesting they play a
role in A toxicity as well as in the deposition of A into senile
plaques associated with Alzheimer's disease (6-9). In addition,
gangliosides regulate the production of various inflammatory mediators,
such as cytokines and inducible nitric-oxide synthase
(iNOS)1 (10, 11). Despite the
evidence of a role for gangliosides in brain pathology, there appears
to be little known about how gangliosides act.
Janus kinase-signal transducers and activators of transcription
(JAK-STAT) signaling pathways have been reported to be involved not
only in the immune response of numerous cytokines but also in the
actions of primarily non-immune mediators such as growth factors and
hormones. Specific subtypes of JAK and STAT molecules are activated by
different signals, resulting in specificity of response (12, 13). The
binding of ligand to its receptor induces assembly of an active
receptor complex and consequent phosphorylation of the
receptor-associated JAKs (JAK1, JAK2, JAK3, and TYK2). Phosphorylated
JAKs lead to the activation of neighboring JAKs, receptor subunits, and
several other substrates. Phosphorylation of JAKs provides the docking
sites for STATs, which in turn become phosphorylated on tyrosine and
serine residues; the phosphorylation of both amino acid species is
required for full STAT activity. Phosphorylated STATs are released from
the receptor complex and form dimers. These dimers translocate to the
nucleus where they directly bind to the promoter region of specific
target genes, thus regulating transcription of these genes, many of
which are involved in immune responses (13-16).
Microglia are the major immune effector cells in the brain, and
microglial activation is an early event in central nervous system
inflammation (17, 18). Previously, we demonstrated that gangliosides
could activate microglia, inducing release of inflammatory mediators
such as tumor necrosis factor- and nitric oxide (NO) (10, 19). Here
we show that the molecular mechanisms underlying this
gangliosides-induced activation of microglia include triggering of the
JAK-STAT signaling pathway.
 |
EXPERIMENTAL PROCEDURES |
Reagents--
Bovine brain gangliosides mixture, GM1 and GD1a,
was purchased from Matreya (Pleasant Gap, PA). Asialoganglioside GM1
was from Sigma. Rat IFN- ,
-cyano-(3,4-dihydroxy)-N-benzylcinnamide (AG490), and
PD98059 were from Calbiochem. Anthrobacter ureafaciens neuraminidase was from Sigma. Dulbecco's modified Eagle's medium and
minimal essential medium were from Invitrogen. Antibodies against
STAT1, Tyr-701-phosphorylated STAT1, Ser-727-phosphorylated STAT1, and
Tyr-705-phosphorylated STAT3 were from Cell Signaling Technology
(Beverly, MA). Antibodies against phosphorylated ERK, ERK, and
phosphorylated p38 were from Calbiochem. Antibodies against phosphorylated JAK1 and -2 were from Affinity Bioreagents (Denver, CO).
Cell Culture--
Primary microglia were cultured from the
cerebral cortices of 1-3-day-old Sprague-Dawley rats as described
previously (10). Briefly, the cortices were triturated into single
cells in minimal essential medium containing 10% fetal bovine serum
(HyClone, Logan, UT) and plated in 75-cm2 T-flasks (0.5 hemisphere/flask) for 2-3 weeks. Microglia were then detached from the
flasks by mild shaking and filtered through a nylon mesh to remove
astrocytes. Cells were plated in 6-well plates (7 × 104 cells/well), 60-mm dishes (5 × 105
cells/dish), or 100-mm dishes (106 cells/well). One hour
later, the cells were washed to remove unattached cells before being
used in experiments. BV2 immortalized murine microglia cells were from
Dr. E. J. Choi. The BV2 cell line was grown in Dulbecco's
modified Eagle's medium and supplemented with 5% fetal bovine serum.
Cells were serum-starved overnight before treatment with gangliosides.
Electrophoretic Mobility Shift Assay (EMSA)--
Cells were
harvested and suspended in 9 times packaged cell volume of a hypotonic
solution (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM
dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride)
including 0.5% Nonidet P-40. Cells were centrifuged at 500 × g for 10 min at 4 °C, and the pellet (nuclear fraction) was saved. The nuclear fractions were resuspended in a buffer containing 20 mM HEPES, pH 7.9, 20% glycerol, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, and 1 mM
phenylmethylsulfonyl fluoride, incubated on ice for 60 min with
occasional gentle shaking, and centrifuged at 12,000 × g for 20 min. The crude nuclear proteins in the supernatant
were collected and stored at 70 °C for EMSA. EMSA was performed
for 30 min on ice in a volume of 20 µl, containing 4 µg of nuclear
protein extract in a reaction buffer containing 8.5 mM
EDTA, 8.5 mM EGTA, 8% glycerol, 0.1 mM
ZnSO4, 50 µg/ml poly(dI-dC), 1 mM
dithiothreitol, 0.3 mg/ml bovine serum albumin, 6 mM
MgCl2, and  32P-radiolabeled
oligonucleotide probe (3 × 104 cpm), with or without
20-50-fold excess unlabeled probe. In supershift experiments, protein
extracts were incubated with 0.2-0.5 µg of STAT1 and STAT3
antibodies (Santa Cruz Biotechnology) for 30 min prior to the addition
of 32P-labeled probe. DNA-protein complexes were separated
on 6% polyacrylamide gels in Tris/glycine buffer. The dried gels were
exposed to x-ray film. The following double-stranded oligonucleotide
was used in these studies: GAS/ISRE, 5'-AAGTACTTTCAGTTTCATATTACTCTA-3',
27 bp (Santa Cruz Biotechnology, Inc., sc-2537). 5'-End-labeled probes were prepared with 40 µCi of [ -32P]ATP using T4
polynucleotide kinase (Promega) and were purified on Quick Spin Columns
Sephadex G-25 (Roche Molecular Biochemicals).
Reverse Transcription-PCR--
Total RNA was extracted using
RNAzol B (Tel-Test Inc.) and cDNA was prepared using reverse
transcriptase that originated from avian myeloblastosis virus (Takara),
according to the manufacturer's instructions. PCR was performed with
30 cycles of sequential reactions as follows: 94 °C for 30 s,
55 °C for 30 s, and 72 °C for 30 s. Oligonucleotide
primers were purchased from Bioneer (Seoul, Korea). The sequences of
PCR primers are as follows: (reverse) 5'-GCAGAATGTGACCATCATGG-3' and
(forward) 5'-ACAACCTTGGTGTTGAAGGC-3' for iNOS; (reverse)
5'-AAGGCCGCAGAGAGCAAAAGAAGC-3' and (forward)
5'-CTGGAGAGCACAAACAGCAGAG-3' for ICAM-1; (reverse) 5'-ATGCAGGTCTCTGTCACGCT-3' and (forward) 5'-CTAGTTCTCTGTCATACTGG-3' for
MCP-1; (reverse) 5'-AGATCCACAACGGATACATT-3' and (forward) 5'-TCCCTCAAGATTGTCAGCAA-3' for glyceraldehyde-3-phosphate dehydrogenase.
Western Blot Analysis--
Cells were washed twice with cold
phosphate-buffered saline and then lysed in ice-cold modified RIPA
buffer (50 mM Tris-HCl, pH 7.4, 1% Nonidet P-40, 0.25%
sodium deoxycholate, 150 mM NaCl, 1 mM
Na3VO4, and 1 mM NaF) containing
protease inhibitors (2 mM phenylmethylsulfonyl fluoride,
100 µg/ml leupeptin, 10 µg/ml pepstatin, 1 µg/ml aprotinin, and 2 mM EDTA). The lysates were centrifuged for 10 min at
12,000 × g at 4 °C, and the supernatant was
collected. Proteins were separated by SDS-PAGE and transferred to
nitrocellulose membrane. The membrane was incubated with primary
antibodies and peroxidase-conjugated secondary antibodies (Vector
Laboratories, Burlingame, CA) and then visualized using an enhanced
chemiluminescence system (Sigma).
Determination of NO Release--
Media nitrite concentration was
measured as an indication of NO release. Following the indicated cell
incubations, 50 µl of culture medium was removed and mixed with
an equal volume of Griess reagent (0.1% naphthylethylenediamine, 1%
sulfanilamide, 2.5% H3PO4), and absorbance of
the mixture at 540 nm was measured.
Enzymatic Digestion of Sialic Acid--
Neuraminidase derived
from A. ureafaciens was used for cleaving sialic acids
residues from gangliosides. Gangliosides were dissolved in 10 mM sodium acetate buffer, pH 5.0, containing 1 µg of
sodium cholate per µl and were incubated with A. ureafaciens neuraminidase (Sigma) at 37 °C for 2 h.
 |
RESULTS |
Gangliosides Induce Nuclear Factor Binding to GAS/ISRE
Elements--
Functional GAS/ISRE elements are found in the promoter
regions of several inflammation-related genes, such as iNOS, and these elements are known to bind the phosphorylated STAT dimer (15, 20-22).
In an attempt to explore the molecular mechanism of gangliosides on microglial activation, we investigated whether STATs could be
involved in gangliosides-induced activation of microglia. We first
examined the transcript level of iNOS in gangliosides-treated rat
primary microglia. Gangliosides markedly induced iNOS mRNA within
1 h, suggesting that gangliosides directly regulate NO production
at the level of transcription (Fig.
1A). Our assumption was
subsequently evaluated by EMSA using a -32P-labeled
consensus GAS/ISRE oligonucleotides probe. After the cells were treated
with 50 µg/ml brain-derived ganglioside mixture for the indicated
times, nuclear extracts were prepared and then analyzed by EMSA. The
specific binding complex was detected in nuclear extracts from
gangliosides-treated rat primary and murine BV2 microglia (Fig. 1,
A and B). Time course analysis showed that gangliosides rapidly induced the nuclear factor binding within 5 min
and that the binding activity was decreased to basal levels after 30 min in both microglial cell types (Fig. 1B and data not shown). The specificity of the shifted bands was confirmed by competition assay using excess amounts of unlabeled oligonucleotides (Fig. 1B). In addition, gel shift assay showed that the
binding complex was diminished by addition of anti-STAT1 and
anti-STAT3, indicating that both STAT1 and STAT3 are constituents of
the nuclear factor binding complex (Fig. 1C). These results
show that functional GAS/ISRE elements may be involved in
gangliosides-induced activation of microglia.

View larger version (41K):
[in this window]
[in a new window]
|
Fig. 1.
Gangliosides stimulate iNOS transcription and
nuclear factor binding to GAS/ISRE elements. A, transcript
level of iNOS and nuclear factor binding to GAS/ISRE element in
gangliosides-treated rat primary microglia. Rat primary microglial
cells were treated with or without 50 µg/ml brain gangliosides
mixture (Gmix) for 1 h, after which total RNA was
isolated, and levels of iNOS mRNA were measured using an
RT-PCR-based assay (left). Cells were treated with Gmix for
5 min, after which nuclear extracts were prepared and assayed for the
amount of binding activity to GAS/ISRE oligonucleotides using EMSA
(right). GAPDH, glyceraldehyde-3-phosphate
dehydrogenase. B, time course analysis of nuclear factor
binding activity in mouse BV2 microglial cells. BV2 cells were treated
with 50 µg/ml Gmix for the indicated periods. Nuclear extracts were
prepared, and binding activity to GAS/ISRE oligonucleotides was
determined by EMSA. Data are representative of four independent
experiments. C, gel shift assay using anti-STAT1 and
anti-STAT3 in BV2 cells. After cells were treated with 50 µg/ml Gmix
for 5 min, gel shift assays were performed as described above with the
exception that nuclear extracts were incubated with 0.2-0.5 µg of
STAT1 and STAT3 antibodies for 30 min prior to the addition of
32P-labeled probe. *, inset is a short-exposed
autograph of the upper band (dotted box).
|
|
Gangliosides Induce the Phosphorylation of STAT1 and
STAT3--
Essential roles for STAT signaling in brain inflammatory
response have emerged (20, 23, 24). Because gangliosides rapidly induced the GAS/ISRE-nuclear factor binding, we examined whether gangliosides indeed caused phosphorylation of STAT proteins. Primary microglial cells were stimulated with 50 µg/ml gangliosides for the
indicated times, and the levels of phosphorylated STAT1 were determined
by Western blot analysis using antibodies against Tyr-701-STAT1 and
Ser-727-STAT1. Both phosphorylations of STAT1 occurred within 1 min of
gangliosides addition and then decreased at 30 min (Fig. 2A). Similar patterns of
phosphorylation were observed in lysates from murine BV2 microglial
cells, where incubation of cells with gangliosides resulted in STAT1
phosphorylation on tyrosine and serine residues, with phosphorylation
levels returning to basal at 30 min (Fig. 2B). In addition
to phosphorylation of STAT1, we detected gangliosides-induced
phosphorylation of STAT3 in both microglial cell types. The pattern of
STAT3 tyrosine phosphorylation appeared similar to that of STAT1
phosphorylation (Fig. 2, A and B). The Western
blotting data show that gangliosides trigger rapid phosphorylation of
STAT1 and STAT3, suggesting their involvement in gangliosides-induced
microglial activation. The phosphorylation patterns of both STAT1 and
STAT3 determined by Western blotting correlate with the binding
activity results from EMSA.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 2.
Gangliosides induce the phosphorylation of
STAT1 and STAT3 in microglial cells. Rat primary microglial cells
(A) and mouse BV2 microglial cells (B) were
serum-starved for 12 h and then stimulated with 50 µg/ml Gmix
for the indicated times. Cell lysates were separated by 10% SDS-PAGE
and Western blots probed with anti-pSTAT1 (Tyr-701), anti-pSTAT1
(Ser-727), or pSTAT3 (Tyr-705). The membrane was then stripped and
analyzed with anti-STAT1 antibody to determine loading. Data are
representative of four independent experiments.
|
|
Gangliosides Induce Phosphorylation and Activation of JAK1 and
JAK2--
Phosphorylation of STATs depends on the activation of JAKs
(25). JAKs both functionally and physically associate with cytokine signaling. In particular, activation of JAK1 and JAK2 provides a
molecular explanation for cellular actions of a broad range of
cytokines (26, 27). Thus, we investigated whether JAK1 and JAK2 could
be involved in gangliosides-induced STAT phosphorylation. Primary rat
microglial cells were stimulated with 50 µg/ml gangliosides for the
indicated times, and cell lysates were Western blotted using antibodies
directed against phosphorylated JAK1 and JAK2. The data presented in
Fig. 3A show that following
addition of gangliosides to cells, phosphorylation of both JAK1 and
JAK2 occurred within 5 min, after which phosphorylation levels
returned to basal levels by 30 min. The involvement of JAK signaling in
gangliosides-induced microglial activation was also shown using a
second, independent approach. The pharmacological agent AG490 is known
to inhibit the phosphorylation of both JAK1 and JAK2 (20). We found
that pretreatment of rat primary microglial cells with AG490
effectively reduced gangliosides-induced phosphorylation of STAT1 and
STAT3 (Fig. 3B). In addition, AG490 inhibited the nuclear
factor binding to GAS/ISRE nucleotides in gangliosides-treated
microglial cells (Fig. 3C). These results indicate that
gangliosides induce phosphorylation and activation of STAT1 and STAT3
through phosphorylation and activation of JAK1 and JAK2.

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 3.
Gangliosides stimulate phosphorylation of
JAK1 and JAK2 in rat primary microglial cells. A,
phosphorylated levels of JAK1 and -2 in gangliosides-treated rat
primary microglial cells. Cells were serum-starved for 12 h and
then stimulated with 50 µg/ml Gmix for 5 min. The phosphorylation of
JAK1 and JAK2 was determined by Western blot analysis using antibodies
specific for phospho-JAK1 or -2. B, inhibition of
gangliosides-induced phosphorylation by AG490. Cells were pretreated
with 10 µM AG490 for 1 h and then stimulated with 50 µg/ml Gmix for 2 min. Western blots were probed with anti-pSTAT1
(Tyr-701) and pSTAT3 (Tyr-705). The membrane was subsequently stripped
and probed with anti-STAT1 and STAT3 antibodies. C,
inhibition of nuclear factor binding to GAS/ISRE oligonucleotides by
AG490. Cells were pretreated with 10 µM AG490 for 1 h and then stimulated with 50 µg/ml Gmix for 5 min. Nuclear extracts
were prepared, and binding activity to GAS/ISRE oligonucleotides was
determined by EMSA. *, inset is a short-exposed autograph of
the upper band (dotted box).
|
|
Gangliosides Stimulate STAT-responsive Inflammatory Gene
Expression--
Brain inflammatory responses are coordinated by the
production of cytokines, chemokines, and reactive oxygen species (17). The above data indicate that gangliosides-induced microglial activation may be mediated, at least in part, by JAK-STAT-dependent
transcriptional responses. Therefore, we examined the transcript level
of genes that have been reported previously (29, 30) to have functional GAS elements and act as mediators of inflammation, namely monocyte chemoattractant protein-1 (MCP-1) and intercellular adhesion molecule-1 (ICAM-1). Rat primary microglial cells and BV2 cells were stimulated with 50 µg/ml gangliosides for 3 h, and total RNA was extracted for RT-PCR analysis. Addition of gangliosides rapidly increased the
mRNA levels of both MCP-1 and ICAM-1, as did IFN- , which was
included as a positive control (Fig.
4A). Pretreatment with AG490
significantly inhibited gangliosides-induced transcription of both
genes (Fig. 4B). These findings demonstrate that
gangliosides trigger STAT-dependent transcriptional
activation of inflammatory genes in microglia.

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 4.
Gangliosides stimulate transcription of
STAT-responsive inflammatory genes in microglial cells. AG490
suppresses this transcription. A, gangliosides-induced
transcription of MCP-1 and ICAM-1 in rat primary microglial cells.
Cells were treated for 3 h with 50 µg/ml Gmix or 10 units/ml
IFN- . Total RNA was isolated and analyzed for levels of MCP-1 and
ICAM-1 mRNA using an RT-PCR-based assay. The transcription of
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
measured for normalization. B, the effect of AG490 on
gangliosides-induced transcription. Cells were pretreated with 10 µM AG490 for 1 h and then stimulated with 50 µg/ml
Gmix for 3 h. mRNA expression of MCP-1 and ICAM-1 was detected
using an RT-PCR-based assay. Data are representative of three
independent experiments.
|
|
AG490 Reduces Gangliosides-induced Release of NO--
NO is known
as an important physiological signaling molecule in the brain. Aberrant
iNOS expression and excessive NO production are observed in various
pathophysiological conditions (31). Previously, we showed (10) that
gangliosides-induced microglial activation was accompanied by induction
of NO release. Thus, we tested whether gangliosides induced NO release
via JAK-STAT signaling. First, we examined the effect of JAK inhibition
on gangliosides-induced transcription of iNOS in rat primary microglial
cells. RT-PCR analysis showed that the inhibitor AG490 reduced mRNA
levels of iNOS (Fig. 5). Second, we
investigated the effect of AG490 on NO release. In these studies, the
ERK inhibitor, PD98059, was also used since we have shown previously
(10) that it reduced gangliosides-induced NO release. In the presence
of AG490, microglial cells were treated with 50 µg/ml gangliosides
for 48 h, and the amount of NO produced was determined by
measuring the amount of nitrite converted from NO in the media. AG490
significantly reduced gangliosides-enhanced NO release, as did PD98059
(Fig. 5). Compared with cells treated with gangliosides alone, NO
release was reduced to 38.6 ± 4.3 and 25.2 ± 14% in cells
co-treated with PD98059 and AG490, respectively. These results are
consistent with the results shown in Figs. 3 and 4. The findings
indicate that JAK-STAT signaling is required for NO release and provide
evidence of the critical functional involvement of JAK-STAT signaling
in gangliosides-induced microglial activation.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 5.
AG490 reduces gangliosides-stimulated NO in
rat primary microglial cells. A, inhibition of
gangliosides-induced iNOS transcription by AG490. Cells were pretreated
with 10 µM AG490 for 1 h and then stimulated with 50 µg/ml Gmix for 3 h. mRNA expression of iNOS was detected by
RT-PCR analysis. B, inhibition of gangliosides-induced NO
release by AG490. Cells were treated with 50 µg/ml Gmix for 48 h
in the presence or absence of AG490 or PD98059. The amount of NO was
determined by measuring the amount of nitrite in the media, as
described under "Experimental Procedures." GAPDH,
glyceraldehyde-3-phosphate dehydrogenase.
|
|
ERK Activity Appears to be Regulated by JAK Activation--
There
are several reports (32, 33) showing that the transcriptional activity
of STATs is regulated through mitogen-activated protein kinases
(MAPKs). MAPKs are considered as common intracellular signaling
molecules involved in microglial activation. Previous reports by others
and us (10, 34) showed that gangliosides induced activation of MAPKs in
microglia. In the present study, we used pharmacological inhibitors to
examine possible cross-talk between the JAK-STAT and MAPKs
signaling pathways. When primary rat microglial cells were
pretreated for 2 h with the JAK inhibitor AG490,
gangliosides-induced activation of ERK1/2 was significantly reduced
compared with controls with no AG490 (Fig.
6). In contrast, no significant
suppression of p38 was observed under this condition. However, in the
presence of PD98059, an ERK inhibitor, not only ERK but also p38
activation was completely inhibited. These results indicate that
gangliosides-stimulated JAK activation leads to activation of ERK in
microglial cells. These pharmacological studies also indicate that
gangliosides-stimulated activation of p38 may not be due to activation
of ERK by JAK.

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 6.
Activation of ERK1/2 follows JAK-STAT
activation in gangliosides-treated primary microglial cells.
Primary microglial cells were pretreated with AG490 or PD98059 for
1 h and then treated with 50 µg/ml Gmix for 30 min. Cell lysates
were separated by 10% SDS-PAGE and Western blots probed with
anti-phospho-ERK and anti-phospho p38, respectively. The membrane was
then stripped and probed with anti-ERK antibody. At least four
experiments were independently performed, and representative data are
shown in this figure.
|
|
Sialic Acid Residues Are Important for Gangliosides-induced
Phosphorylation of STAT--
The major types of gangliosides in brain
are GM1, GD1a, GD1b, GT1b, and GQ1b. These gangliosides differ with
respect to the number and position of sialic acid residues attached to
the carbohydrates (35). The approximate percentages of each ganglioside
present in the brain gangliosides mixture used in the current study are 18% GM1, 55% GD1a, 15% GD1b, 10% GT1b, and 2% others. To address whether the structural diversity of gangliosides affected activation of
STAT, we compared the effect of GM1, which has one molecule of sialic
acid, with GD1a, which has two molecules of sialic acid, on
phosphorylation of STAT1. Primary microglial cells were treated with
GM1 or GD1a for 2 min, and levels of phosphorylated STAT1 were
determined by Western blot analysis using antibodies against Tyr-701-STAT1. The data in Fig.
7A show both GM1 and GD1a
stimulated phosphorylation of STAT1 within 2 min. The level of STAT1
phosphorylation stimulated by either GM1 or GD1a was similar to that
caused by the gangliosides mixture, suggesting that the number of
sialic acid residues per ganglioside molecule has little effect on the phosphorylation of STAT1 in microglial cells (Fig. 7A).
Because sialic acid residues are characteristic of gangliosides, we
examined whether sialic acid residues were important for
gangliosides-stimulated STAT phosphorylation. Gangliosides were
preincubated with either 550 or 1000 units/ml A. ureafaciens
neuraminidase, which is known to release sialic acid attached to an
internal galactose in any gangliosides including GM1 (36, 37). Primary
microglia cells were stimulated with gangliosides or
neuraminidase-treated gangliosides (desialylated gangliosides)
for 2 min, and levels of phosphorylated STAT1 were determined by
Western blot analysis. The data presented in Fig. 7B show a
dose-dependent inhibitory effect of neuraminidase treatment on phosphorylation of STAT1, indicating that sialic acid
residues are required for stimulation of JAK-STAT signaling. To rule
out the possibility that these reductions are due to contaminating sialic acid or neuraminidase, we compared the effect of GM1 and asialo-GM1(Sigma) on phosphorylation of STAT and transcription of
STAT-responsive genes. Consistent with Fig. 7, not only the phosphorylation of STAT1 and STAT3 but also the transcriptions of iNOS,
MCP-1, and ICAM-1 were not induced in asialo-GM1-treated primary
microglial cells (Fig. 8). Taken
together, these results suggest that the presence of sialic acid
residues is important for gangliosides-stimulated JAK-STAT signaling,
although the number of sialic residues per ganglioside molecule may not
influence phosphorylation.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 7.
The sialic acid residue of gangliosides is
necessary for activation of JAK-STAT signaling. A, effect of
GM1 and GD1a on phosphorylation of STAT1. Primary microglial cells were
treated with 20 µg/ml GM1 or GD1a for 2 min. Cell lysates were
subjected to Western blot analysis, and levels of phosphorylated STAT1
were determined using anti-pSTAT1 (Tyr-701). B, effects of
neuraminidase on gangliosides-induced phosphorylation of STAT1 in
primary microglial cells. To remove the sialic acid residue,
gangliosides were preincubated with 550 or 1000 units/ml A. ureafaciens neuraminidase as described under "Experimental
Procedures." Cells were treated with the indicated gangliosides or
the desialylated gangliosides for 2 min, after which cell lysates were
prepared, separated by 10% SDS-PAGE, Western blotted, and probed using
anti-pSTAT1 (Tyr-701). The membrane was then stripped and probed with
anti-STAT1 antibody.
|
|

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 8.
Asialo-GM1 does not activate the JAK-STAT
signaling in primary microglial cells. A, effect of GM1 and
asialo-GM1 on phosphorylation of STAT. Primary microglial cells were
treated with 20 µg/ml of GM1 or asialo-GM1 for 2 min. Cell lysates
were subjected to Western blot analysis, and levels of phosphorylated
STAT were determined using anti-pSTAT1 and anti-pSTAT3. Con,
control. B, effect of GM1 and asialo-GM1 on STAT-responsive
transcription. Total RNA was isolated and analyzed for levels of iNOS,
MCP-1, and ICAM-1 mRNA using an RT-PCR-based assay.
|
|
 |
DISCUSSION |
Increasing evidence indicates that gangliosides act not only as
mediators for cellular interactions but also as modulators of signal
transduction in a variety of cellular events. These functions appear to
occur simultaneously and influence each other (38). Identification of
the precise mechanisms underlying how gangliosides regulate cellular
responses has been the subject of many investigations, but it appears
there is still much that is unknown (11, 34, 39). In this study, we
reveal that gangliosides directly induce the activation of JAK-STAT
signaling, a key pathway in inflammation, which leads to the expression
of several inflammation-associated genes.
JAK-STAT signaling has been reported to be closely involved in
inflammation. Although STAT proteins were discovered during the course
of analysis of interferon signaling, recent studies (40-42) have
revealed that STAT signaling can account for various cellular responses
to a number of cytokines, growth factors, and hormones. IL-4 and IL-13
stimulate enhanced expression of major histocompatibility complex class
II, CD23, IL-4Ra chain, and Ig class switching to IgE and IgG via
activation of STAT6 (43, 44). The common cytokine receptor -chain,
which is shared by receptors for IL-2, -4, -7, -9, and -15, associates
with JAK3, thus resulting in STAT-dependent immune
responses (45, 46). Prolactin, erythropoietin, and growth hormone are
all known to activate JAK2 (47).
The functional association between cytokine signaling and JAK-STAT
signaling prompted us to examine the involvement of STATs in
gangliosides-induced inflammatory responses. Consistent with a
connection between gangliosides and STAT activity, we found that
gangliosides treatment of brain microglial cells increased the binding
activity of a nuclear factor to a consensus GAS/ISRE element (Fig. 1).
It has been reported that STAT1 and -3 are major STAT types that bind
GAS and ISRE elements, and that they function to regulate the
transcription of numerous genes (21, 24). By using supershift
antibodies for STAT1 and STAT3, we determined that they are
constituents of nuclear factor binding complex to the GAS/ISRE element
in gangliosides-stimulated microglial cells (Fig. 1C). At
the present time, we cannot clearly identify the individual bands since
all the three bands were reduced by addition of not only anti-STAT1 but
also anti-STAT3. However, our EMSA data and Western blotting data
convincingly proved the involvement of STAT1 and STAT3 in
gangliosides-induced inflammatory responses. Next, we investigated
whether gangliosides could induce the phosphorylation of these
particular STATs. As expected, phosphorylation of STAT1 and -3 was
induced within 1 min and then rapidly decreased to basal levels (Fig.
2). The kinetics of these phosphorylation events were consistent with
the timing of binding activity to GAS/ISRE elements. These results show
that STAT1 and -3 may directly mediate gangliosides-induced microglial
activation. NF- B is also reported to be involved in
gangliosides-induced microglial activation, but it is considered to be
a pathway common to a range of microglial activators (10). Thus, it may
be that early activation of STATs by gangliosides is a specific
mechanism underlying gangliosides-induced microglial activation.
Phosphorylation of JAKs leads to their activation, and activated JAKs
phosphorylate and hence activate STATs. We examined the effect of
gangliosides on JAK1 and JAK2 to determine the cause of STAT1 and STAT3
phosphorylation. We found that both JAK1 and JAK2 were phosphorylated
within 1 min of the addition of gangliosides (Fig. 3). Furthermore,
AG490, a JAK inhibitor, diminished both gangliosides-enhanced
phosphorylation of STATs and nuclear factor binding activity. These
data provide strong evidence to indicate that gangliosides activate
STATs through activation of JAKs.
In general, inflammatory stimuli induce release of mediators such as
cytokines, chemokines and cell adhesion molecules (49). Regulation of
mediator release is important for controlling inflammation. We
investigated the transcription of inflammation-associated genes that
contain functional GAS elements in their promoters. RT-PCR analysis
showed that gangliosides enhanced the transcript level of ICAM-1 and
MCP-1 within 3 h, whereas pretreatment with AG490 inhibited this
increase (Fig. 4). These results provide further evidence for
involvement of JAK-STAT inflammatory signaling in gangliosides-induced
microglial activation. Moreover, AG490 significantly reduced
gangliosides-induced NO release, indicating that NO production was
partly dependent on JAK-STAT signaling (Fig. 5). Taken together, these
results suggest that inflammatory mediators including MCP-1, ICAM-1,
and NO may be induced in response to gangliosides through JAK-STAT signaling.
We next examined other signaling events that may be associated with
JAK-STAT activation in gangliosides-treated microglial cells. Having
previously observed that ERKs and p38 MAPKs were activated by
gangliosides, we investigated whether gangliosides-stimulated JAK-STAT
signaling was linked to activation of ERKs and p38 MAPKs. By using
pharmacological inhibitors, we found that gangliosides-stimulated activation of JAK resulted in phosphorylation of ERK1/2 (but not p38)
(Fig. 6), suggesting cross-talk between JAK and ERK pathways. Interestingly, inhibition of ERK by PD98059 resulted in complete inhibition of p38 activation, indicating cross-talk between different MAP kinase pathways. Because AG490 only partially reduced the phosphorylation of ERK, but PD98059 completely inhibited the activation of ERKs and p38, it is likely that activation of p38 is downstream of
ERK activation and that any connection occurs via signaling molecules
other than JAK-STATs. The activation profile of signaling molecules
seems to depend on stimulators and/or cell types. Furthermore, upstream
and downstream signaling molecules may be specifically affected by
cross-talk and convergence in a particular environment. For example,
Gouni-Berthold et al. (34) recently reported that gangliosides had no effect on phosphorylation of p38 in vascular smooth
muscle cells, and that platelet-derived growth factor-BB-induced phosphorylation of p38 was not influenced by PD98059. In contrast, both
MAPKs are activated by lipopolysaccharides and gangliosides in primary
glial cells (10, 50). In view of the fact that gangliosides-induced
activation of JAK-STAT signaling occurs more rapidly than activation of
ERKs, and that inhibition of JAK activation reduced ERKs activation, it
appears gangliosides-stimulated JAK-STAT signaling regulates ERKs
activation in microglial cells. In contrast, p38 activation does not
seem to be linked to JAK-STAT signaling, even though it too plays a
role in microglial activation.
Gangliosides are amphipathic molecules that belong to a class of
anionic glycosphingolipids. They contain sialic acid residues (N-acetylneuraminic acids), linked to the sugar residues of
a ceramide oligosaccharide. It has been reported (34, 51) that different types of gangliosides have distinct roles in several cell
types. To gain insight into the mechanism underlying JAK-STAT activation by gangliosides, we investigate whether GM1 and GD1a, the
major types of gangliosides mixture used in these studies (18 and 55%,
respectively), had different effects on STAT activation. Despite
containing different numbers of sialic acid residues per molecule, GM1
containing one and GD1a containing two, both gangliosides activated
STAT1 to a similar extent, which was similar to the activation caused
by the gangliosides mixture. Although the different number of sialic
acid residues on a gangliosides appeared to have no influence on STAT
phosphorylation, the presence of sialic acid on a gangliosides was
critical, since removal of sialic acid by neuraminidase resulted in
reduced STAT1 phosphorylation (Fig. 7). These results are further
confirmed by experiments to compare activities of GM1 and asialo-GM1.
Unlike GM1, asialo-GM1 did not induce phosphorylation of STAT or
expression of STAT-responsive genes including iNOS (Fig. 8) Thus, it
appears sialic acid residues of gangliosides are important for STAT
activation, and one residue per molecule is sufficient. However, we do
not exclude the possibility that other moieties of gangliosides also
importantly affect JAK-STAT signaling in microglial cells.
It is intriguing, but unresolved, as to how gangliosides stimulate
phosphorylation of JAKs. One possibility is that gangliosides act by
binding to specific cell surface receptors. However, although galectin-1 and -3 are reported to bind GM1, the specific receptors of
gangliosides have not been clearly elucidated (51). Alternatively, gangliosides may act by modulating other signaling molecules. For
example, there are reports (52-55) that incorporation of gangliosides into plasma membranes regulates CD4, growth factor receptors, and
phospholipase C. It may be that the gangliosides-enriched membrane
domains, assigned as lipid rafts, regulate intermolecular associations
in the plasma membranes. Many transmembrane receptors are reported to
be constitutively or inducibly localized within lipid rafts (36,
56-58). It has been reported that the Src family kinases Rho, FAK,
Lyn, and Lck are associated with ganglioside-enriched lipid rafts (56,
39, 59, 60). Interestingly, a recent report (28) showed that JAK1 and
JAK2 are exclusively localized in lipid rafts of mouse embryonic
fibroblasts. Furthermore, it has been suggested that JAKs interact not
only with STATs but also with several other proteins such as Grb2, Shc,
Vav, Fyn, and c-Abl (25, 48, 61). Based on these reports and our
current findings that JAK-STAT signaling is rapidly activated by
gangliosides, it is possible that gangliosides physically and
functionally associate with certain signaling molecules in membranes,
thereby activating JAKs. In this regard, we are interested in the
composition and functional organization of gangliosides in the
membrane. Further studies are needed to clarify how gangliosides act to
initiate JAK-STAT signaling. These studies will provide important
information regarding microglial activation.
In conclusion, our findings suggest that gangliosides rapidly trigger
JAK-STAT inflammatory signaling, resulting in brain microglial
activation. Our studies indicate that gangliosides-stimulated JAK-STAT
signaling mediates several important inflammatory events, including
production of NO and transcription of inflammatory mediators. Gangliosides are now emerging as important factors in signaling pathways and neuronal diseases. Our data provide significant new information regarding the molecular mechanisms underlying
gangliosides-induced microglial inflammation, and such knowledge will
assist in the better understanding of the pathogenesis of brain disease.
 |
ACKNOWLEDGEMENT |
We thank Dr. E. J. Choi (Korea
University, Seoul, Korea) for providing BV2 cells.
 |
FOOTNOTES |
*
This work was supported by Grant R01-2000-00164 from the
Basic Research Program of the KOSEF and by Critical Technology
21[01-J-LF-B-77 Grant from the Korea Ministry of Science and
Technology (to I. J.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Both authors contributed equally to this paper.
§
To whom correspondence should be addressed: Dept. of Pharmacology,
School of Medicine, Ajou University, Suwon, 442-721, Korea. Tel.:
82-31-219-5061; Fax: 82-31-219-5069; E-mail: jouilo@madang.ajou.ac. kr.
Published, JBC Papers in Press, August 20, 2002, DOI 10.1074/jbc. M203885200
 |
ABBREVIATIONS |
The abbreviations used are:
iNOS, inducible
nitric-oxide synthase;
NO, nitric oxide;
JAK-STAT, JAK-STAT, Janus
kinase-signal transducers and activators of transcription;
ERK, extracellular signal-regulated kinase;
MAPKs, mitogen-activated protein
kinases;
EMSA, electrophoretic mobility shift assay;
GAS/ISRE, -interferon-activated sequence/interferon- -stimulated response
element;
RT, reverse transcription;
MCP-1, monocyte chemoattractant
protein-1;
ICAM-1, intercellular adhesion molecule-1;
IFN, interferon;
IL, interleukin.
 |
REFERENCES |
| 1.
|
Derry, D. M.,
and Wolfe, L. S.
(1967)
Science
158,
1450-1452[Abstract/Free Full Text]
|
| 2.
|
Rodden, F. R.,
Wiegandt, H.,
and Bauer, B. L.
(1991)
J. Neurosurg.
74,
606-619[Medline]
[Order article via Infotrieve]
|
| 3.
|
Michikawa, M.,
Gong, J.,
Fan, Q.,
Sawamura, N.,
and Yanagisawa, K.
(2001)
J. Neurosci.
21,
7226-7235[Abstract/Free Full Text]
|
| 4.
|
Blennow, K.,
Davidsson, P.,
Walin, A.,
Fredman, P.,
Gottfries, C. G.,
Karlsson, I.,
Mansson, J. E.,
and Svennerholm, L.
(1991)
Arch. Neurol.
48,
1032-1035[Abstract/Free Full Text]
|
| 5.
|
Gisslen, M.,
Hagberg, L.,
Norkransn, G.,
Lekman, A.,
and Fredman, P.
(1997)
J. Neurovirol.
3,
148-152[Medline]
[Order article via Infotrieve]
|
| 6.
|
Yanagisawa, K.,
Okada, A.,
Suzuki, N.,
and Ihara, Y.
(1995)
Nat. Med.
1,
1062-1066[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Ledesma, M. D.,
Silva, J. S. D.,
Cassaerts, K.,
Delacourte, A.,
Strooper, B. D.,
and Dotti, C. G.
(2000)
EMBO Rep.
6,
530-535
|
| 8.
|
Mclaurin, J.,
Franklin, T.,
Fraser, P. E.,
and Chakrabartty, A.
(1998)
J. Biol. Chem.
273,
4506-4515[Abstract/Free Full Text]
|
| 9.
|
Wang, S. S.,
Rymer, D. L.,
and Good, T. A.
(2001)
J. Biol. Chem.
276,
42027-42034[Abstract/Free Full Text]
|
| 10.
|
Pyo, H.,
Joe, E.,
Jung, S.,
Lee, S. H.,
and Jou, I.
(1999)
J. Biol. Chem.
274,
34589-34594
|
| 11.
|
Kanda, N.,
and Watanabe, S.
(2001)
J. Immunol.
166,
72-80[Abstract/Free Full Text]
|
| 12.
|
Kishimoto, T.,
Taga, T.,
and Akira, S.
(1994)
Cell
76,
253-262[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Igaz, P.,
Toth, S.,
and Falus, A.
(2001)
Inflamm. Res.
50,
435-441[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Kovarik, P.,
Mangold, M.,
Ramsauer, K.,
Heidari, H.,
Steinborn, R.,
Zotter, A.,
Levy, D. E.,
Muller, M.,
and Decker, T.
(2001)
EMBO J.
20,
91-100[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Park, C.,
and Schindler, C.
(1998)
Methods
15,
175-188[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Wen, Z.,
Zhong, Z.,
and Darnell, J. E.
(1995)
Cell
82,
241-250[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Streit, W. J.,
Walter, S. A.,
and Pennell, N. A.
(1999)
Prog. Neurobiol. (New York)
57,
563-581
|
| 18.
|
Fischer, H.,
and Reichmann, G.
(2001)
J. Immunol.
166,
2717-2726[Abstract/Free Full Text]
|
| 19.
|
Yang, M. S.,
Park, E. J.,
Sohn, S.,
Kwon, H. S.,
Shin, W. H.,
Pyo, H. K.,
Jin, B.,
Choi, K. S.,
Jou, I.,
and Joe, E.
(2002)
Glia
38,
273-280[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Xuan, Y.-T.,
Guo, Y.,
Han, H.,
Zhu, Y.,
and Bolli, R.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
9050-9055[Abstract/Free Full Text]
|
| 21.
|
Ehret, G. B.,
Reichenbach, P.,
Schindler, U.,
Horvath, C. M.,
Fritz, S.,
Nabholz, M.,
and Bucher, P.
(2001)
J. Biol. Chem.
276,
6675-6688[Abstract/Free Full Text]
|
| 22.
|
Kovarik, P.,
Stoiber, D.,
Novy, M.,
and Decker, T.
(1998)
EMBO J.
17,
3660-3668[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Ganster, R. W.,
Taylor, B. S.,
Shao, L.,
and Geller, D. A.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
8638-8643[Abstract/Free Full Text]
|
| 24.
|
Gao, J. J.,
Morrison, D. C.,
Parmely, T. J.,
Russell, S. W.,
and Murphy, W. J.
(1997)
J. Biol. Chem.
272,
1226-1230[Abstract/Free Full Text]
|
| 25.
|
Stark, G. R.,
Kerr, I. M.,
Williams, B. R. G.,
Silvermann, R. H.,
and Schreiber, R. D.
(1998)
Annu. Rev. Biochem.
67,
227-264[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Schindler, C.
(1999)
Exp. Cell Res.
253,
7-14[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
O'Shea, J.
(1997)
Immunity
7,
1-11[Medline]
[Order article via Infotrieve]
|
| 28.
|
Takaoka, A.,
Mitani, Y.,
Suemori, H.,
Sato, M.,
Yokochi, T.,
Noguchi, S.,
Tanaka, N.,
and Taniguchi, T.
(2000)
Science
288,
2357-2360[Abstract/Free Full Text]
|
| 29.
|
Tessitore, A.,
Pastore, L.,
Rispoli, A.,
Cilenti, L.,
Toniato, E.,
Flati, V.,
Farina, A. R.,
Frati, L.,
Gulino, A.,
and Martinotti, S.
(1998)
Eur. J. Biochem.
258,
968-975[Medline]
[Order article via Infotrieve]
|
| 30.
|
Zhou, Z. H.,
Chaturvedi, P.,
Han, Y. L.,
Aras, S., Li, Y. S.,
Kolattukudy, P. E.,
Ping, D.,
Boss, J. M.,
and Ransohoff, R. M.
(1998)
J. Immunol.
160,
3908-3916[Abstract/Free Full Text]
|
| 31.
|
Ganster, R. W.,
and Geller, D. A.
(2000)
in
Nitric Oxide: Biology and Pathobiology
(Ignaro, L., ed)
, pp. 129-156, Academic, San Diego
|
| 32.
|
David, M.,
Petricoin, E., III,
Benjamin, C.,
Pine, R.,
Weber, M. J.,
and Lancer, A. C.
(1995)
Science
269,
1721-1723[Abstract/Free Full Text]
|
| 33.
|
Takaoka, A.,
Tanaka, N.,
Mitani, Y.,
Miyazaki, T.,
Fujii, H.,
Sato, M.,
Kovarik, P.,
Decker, T.,
Schlessinger, J.,
and Taniguchi, T.
(1999)
EMBO J.
18,
2480-2488[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Gouni-Berthold, I.,
Seul, C., Ko, Y.,
Hescheler, J.,
and Sachinidis, A.
(2001)
Hypertension
38,
1030-1037[Abstract/Free Full Text]
|
| 35.
|
Dreyfus, H.,
Guerold, B.,
Freysz, L.,
and Hicks, D.
(1997)
Anal. Biochem.
249,
67-78[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Saito, M.,
Sugano, K.,
and Nagai, Y.
(1979)
J. Biol. Chem.
254,
7845-7854[Abstract/Free Full Text]
|
| 37.
|
Kielczynski, W.,
Harrison, L. C.,
and Leedman, P. J.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
1991-1995[Abstract/Free Full Text]
|
| 38.
|
Hakomori, S.
(1990)
J. Biol. Chem.
265,
18713-18716[Abstract/Free Full Text]
|
| 39.
|
Kassahara, K.,
Watanabe, Y.,
Yamamoto, T.,
and Sanai, Y.
(1997)
J. Biol. Chem.
272,
29947-29953[Abstract/Free Full Text]
|
| 40.
|
Fu, X.-Y.,
Kessler, D. S.,
Veals, S. A.,
Levy, D. E.,
and Darnelle, J. E.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
8555-8559[Abstract/Free Full Text]
|
| 41.
|
Kessler, D. S.,
Veaks, S. A., Fu, X. Y.,
and Leavy, D. E.
(1990)
Genes Dev.
4,
1753-1765[Abstract/Free Full Text]
|
| 42.
|
Darnelle, J. E.
(1997)
Science
277,
1630-1635[Abstract/Free Full Text]
|
| 43.
|
Nelms, K.,
Keegan, A. D.,
Zamorano, J.,
Ryan, J. J.,
and Paul, W. E.
(1999)
Annu. Rev. Immunol.
17,
701-738[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Jiang, H.,
Harris, M. B.,
and Rothman, P.
(2000)
J. Allergy Clin. Immunol.
105,
1063-1070[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Johnston, J. A.,
Kawamura, M.,
Kirken, R. A.,
Chen, Y. Q.,
Blake, T. B.,
Shibuya, K.,
Orhaldo, J. R.,
McVicar, D. W.,
and O'Shea, J. J.
(1994)
Nature
370,
151-153[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Bacon, C. M.,
McVicar, D. W.,
Ortaldo, J. R.,
Rees, R. C.,
O'Shea, J. J.,
and Johnston, J. A.
(1995)
J. Exp. Med.
181,
1425-1431[Abstract/Free Full Text]
|
| 47.
|
Imada, K.,
and Leonard, W. J.
(2000)
Mol. Immunol.
37,
1-11[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Wang, W.,
Fuhrer, D.,
Marshall, M.,
and Yang, Y.
(1995)
J. Biol. Chem.
270,
27999-28002[Abstract/Free Full Text]
|
| 49.
|
Laskin, D. L.,
and Pendino, K. J.
(1995)
Annu. Rev. Pharmacol. Toxicol.
35,
655-677[CrossRef][Medline]
[Order article via Infotrieve]
|
| 50.
|
Bhat, N. R.,
Zhang, P.,
Lee, J. C.,
and Hogan, E. L.
(1998)
J. Neurosci.
18,
1633-1641[Abstract/Free Full Text]
|
| 51.
|
Kopitz, J.,
von Retzenstein, C.,
Burchet, M.,
Cantz, M.,
and Gabius, H.
(1998)
J. Biol. Chem.
273,
11205-11211[Abstract/Free Full Text]
|
| 52.
|
Garofalo, T.,
Sorice, M.,
Misasi, R.,
Cinques, B.,
Giammatteo, M.,
Pontieri, G. M.,
Cifone, M. G.,
and Pavan, A.
(1998)
J. Biol. Chem.
273,
35153-35160[Abstract/Free Full Text]
|
| 53.
|
Gouy, H.,
Deterre, P.,
Debre, P.,
and Bismuth, G.
(1994)
J. Immunol.
152,
3271-3281[Abstract]
|
| 54.
|
Meuillet, E.,
Cremel, G.,
Drefus, H.,
and Hicks, D.
(1996)
Glia
17,
206-216[CrossRef][Medline]
[Order article via Infotrieve]
|
| 55.
|
Mitsuda, T.,
Furukawa, K.,
Miyazaki, H.,
Urano, T.,
and Furukawa, K.
(2002)
J. Biol. Chem.
29,
11239-11246
|
| 56.
|
Hader, T.,
and Simons, K.
(1999)
Eur. J. Immunol.
29,
556-562[CrossRef][Medline]
[Order article via Infotrieve]
|
| 57.
|
Kantakamalakul, W.,
Politis, A. D.,
Marecki, S.,
Sullivan, T.,
Ozato, K.,
Fenton, M. J.,
and Vogel, S. N.
(1999)
J. Immunol.
162,
7417-7425[Abstract/Free Full Text]
|
| 58.
|
Simons, K.,
and Toomre, D.
(2000)
Nat. Rev. Mol. Cell. Biol.
1,
31-39[CrossRef][Medline]
[Order article via Infotrieve]
|
| 59.
|
Iwabuchi, K.,
Yamamura, S.,
Primetti, A.,
Handa, K.,
and Hakomori, S.
(1998)
J. Biol. Chem.
273,
9130-9138[Abstract/Free Full Text]
|
| 60.
|
Prinetti, A.,
Iwabuchi, K.,
and Hakomori, S.
(1999)
J. Biol. Chem.
274,
20916-20924[Abstract/Free Full Text]
|
| 61.
|
Danial, N.,
Pernis, A.,
and Rothmann, P.
(1995)
Science
269,
1875-1877[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S.-B. Jeon, H. J. Yoon, S.-H. Park, I.-H. Kim, and E. J. Park
Sulfatide, A Major Lipid Component of Myelin Sheath, Activates Inflammatory Responses As an Endogenous Stimulator in Brain-Resident Immune Cells
J. Immunol.,
December 1, 2008;
181(11):
8077 - 8087.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. J. Yoon, S.-B. Jeon, I.-H. Kim, and E. J. Park
Regulation of TLR2 Expression by Prostaglandins in Brain Glia
J. Immunol.,
June 15, 2008;
180(12):
8400 - 8409.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Yang, M. Luo, R. Li, Y. Huang, R. Zhang, Q. Wu, F. Wang, Y. Li, and X. Yu
Blockage of JAK/STAT signalling attenuates renal ischaemia-reperfusion injury in rats
Nephrol. Dial. Transplant.,
January 1, 2008;
23(1):
91 - 100.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Jou, J. H. Lee, S. Y. Park, H. J. Yoon, E.-H. Joe, and E. J. Park
Gangliosides Trigger Inflammatory Responses via TLR4 in Brain Glia
Am. J. Pathol.,
May 1, 2006;
168(5):
1619 - 1630.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Y. Kim, S. J. Park, E.-h. Joe, and I. Jou
Raft-mediated Src Homology 2 Domain-containing Proteintyrosine Phosphatase 2 (SHP-2) Regulation in Microglia
J. Biol. Chem.,
April 28, 2006;
281(17):
11872 - 11878.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Kuwano, T. Kawahara, H. Yamamoto, S. Teshima-Kondo, K. Tominaga, K. Masuda, K. Kishi, K. Morita, and K. Rokutan
Interferon-{gamma} activates transcription of NADPH oxidase 1 gene and upregulates production of superoxide anion by human large intestinal epithelial cells
Am J Physiol Cell Physiol,
February 1, 2006;
290(2):
C433 - C443.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Sano, A. Tessitore, A. Ingrassia, and A. d'Azzo
Chemokine-induced recruitment of genetically modified bone marrow cells into the CNS of GM1-gangliosidosis mice corrects neuronal pathology
Blood,
October 1, 2005;
106(7):
2259 - 2268.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Yadav, A. Kalita, S. Dhillon, and K. Banerjee
JAK/STAT3 Pathway Is Involved in Survival of Neurons in Response to Insulin-like Growth Factor and Negatively Regulated by Suppressor of Cytokine Signaling-3
J. Biol. Chem.,
September 9, 2005;
280(36):
31830 - 31840.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Giri, N. Nath, B. Smith, B. Viollet, A. K. Singh, and I. Singh
5-Aminoimidazole-4-Carboxamide-1-{beta}-4-Ribofuranoside Inhibits Proinflammatory Response in Glial Cells: A Possible Role of AMP-Activated Protein Kinase
J. Neurosci.,
January 14, 2004;
24(2):
479 - 487.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Lee, S. Cha, M.-S. Lee, G. J. Cho, W. S. Choi, and K. Suk
Role of Antiproliferative B Cell Translocation Gene-1 as an Apoptotic Sensitizer in Activation-Induced Cell Death of Brain Microglia
J. Immunol.,
December 1, 2003;
171(11):
5802 - 5811.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Y. Kim, E. J. Park, E.-h. Joe, and I. Jou
Curcumin Suppresses Janus Kinase-STAT Inflammatory Signaling through Activation of Src Homology 2 Domain-Containing Tyrosine Phosphatase 2 in Brain Microglia
J. Immunol.,
December 1, 2003;
171(11):
6072 - 6079.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Zhu, M. A. Amin, M. J. Kim, K. J. Katschke Jr., C. C. Park, and A. E. Koch
A Novel Function for a Glucose Analog of Blood Group H Antigen as a Mediator of Leukocyte-Endothelial Adhesion via Intracellular Adhesion Molecule 1
J. Biol. Chem.,
June 6, 2003;
278(24):
21869 - 21877.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. J. Park, S. Y. Park, E.-h. Joe, and I. Jou
15d-PGJ2 and Rosiglitazone Suppress Janus Kinase-STAT Inflammatory Signaling through Induction of Suppressor of Cytokine Signaling 1 (SOCS1) and SOCS3 in Glia
J. Biol. Chem.,
April 18, 2003;
278(17):
14747 - 14752.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|